Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

369 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 369 results

Not applicableNot Yet RecruitingNCT06541171
What this trial is testing

A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results

Who this might be right for
Ovarian CancerRecurrent Ovarian Carcinoma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 220
Early research (Phase 1)WithdrawnNCT06161493
What this trial is testing

ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors

Who this might be right for
Ovarian CancerRecurrent Solid Tumors
Haider Mahdi
Testing effectiveness (Phase 2)Active Not RecruitingNCT03787680
What this trial is testing

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 49
Testing effectiveness (Phase 2)Looking for participantsNCT06607692
What this trial is testing

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Who this might be right for
Solid Tumor CancerMedulloblastomaHigh Risk Neuroblastoma+19 more
Fundación de investigación HM 25
Testing effectiveness (Phase 2)Study completedNCT04508803
What this trial is testing

Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

Who this might be right for
Treatment Efficacy
Fudan University 37
Early research (Phase 1)WithdrawnNCT05262842
What this trial is testing

JS001+IMP4297 in Patients With Advanced Cancer

Who this might be right for
Advanced Cancer
Shanghai Junshi Bioscience Co., Ltd.
Not applicableUnknownNCT04582552
What this trial is testing

The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer

Who this might be right for
Ovarian CancerClinical MarkerPARP Inhibitor
Xiaoxiang Chen 60
Testing effectiveness (Phase 2)Looking for participantsNCT06441747
What this trial is testing

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Who this might be right for
Cholangiocarcinoma
Australasian Gastro-Intestinal Trials Group 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT06077877
What this trial is testing

Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Who this might be right for
Neoplasms
GlaxoSmithKline 42
Testing effectiveness (Phase 2)Ended earlyNCT04171700
What this trial is testing

Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes

Who this might be right for
Solid Tumor
pharmaand GmbH 83
Testing effectiveness (Phase 2)Active Not RecruitingNCT05784012
What this trial is testing

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello 34
Testing effectiveness (Phase 2)UnknownNCT04978012
What this trial is testing

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Who this might be right for
Nasopharyngeal CarcinomaNasopharyngeal Cancer
Fudan University 48
Testing effectiveness (Phase 2)UnknownNCT04462809
What this trial is testing

Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma

Who this might be right for
Advanced Malignant Pleural or Peritoneal Mesothelioma
Hospices Civils de Lyon 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Looking for participantsNCT07460180
What this trial is testing

The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer

Who this might be right for
Ovarian CancerEpithelial CancerFallopian Tube Cancer
The Netherlands Cancer Institute 55
Not applicableStudy completedNCT04326023
What this trial is testing

Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)

Who this might be right for
Cancer
University Hospital, Caen 178
Early research (Phase 1)Ended earlyNCT01226901
What this trial is testing

A Phase I Study of MK-4827 for Treatment of Solid Tumors (MK-4827-005)

Who this might be right for
NeoplasmsSolid Tumors
Merck Sharp & Dohme LLC 3
Testing effectiveness (Phase 2)Study completedNCT02854436
What this trial is testing

An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 289
Testing effectiveness (Phase 2)Ended earlyNCT05286827
What this trial is testing

Olaparib in Subjects With Advanced Pancreatic Acinar Cell Carcinoma

Who this might be right for
Pancreatic Acinar Cell Carcinoma
National Cancer Institute (NCI) 5
Testing effectiveness (Phase 2)Study completedNCT01506609
What this trial is testing

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 294
Next Page